US market beckons for pharma firm a year after private equity acquisition

Torbay Pharma has its sights set on the US market, 10 months since it was acquired by private equity firm NorthEdge.

In May 2024, Torbay Pharma brought in Mohammed Nazir as COO and Tara Silvey as CPO. The joint hire strengthened the company’s leadership team but and boosted its North American growth strategy.

The US represents a huge growth opportunity for Torbay Pharma, which is focused on achieving FDA approval in the near future.

Emma Rooth, CEO of Torbay Pharma, said: “The current state of play in the US health sector presents a significant opportunity. It’s not only a chance for us to enter a new and exciting market, but also bolster our supply chain which gives us resilience.

“Many of the products we manufacture, right here in Devon, are already top of the shortage list in the US. I see us as playing an indispensable role Stateside.”

This year so far, Torbay Pharma has made 49 new appointments. Today, more than 250 people work for the company.

The business has made capital investment into its ‘High-Speed Vial’ line, giving the team additional bandwidth to meet customer demand.

Renowned for its specialist expertise in the filling of injectables into both plastic and glass containers, Torbay Pharma has become something of a market leader in this space. This is one area where there has been huge demand (plastic parenteral nutrition (PN) product), particularly within North America.

Torbay Pharma has expanded its footprint from its Paignton base to supply customers in over 20 countries globally.

Now, backed by NorthEdge, there are big ambitions for the future.

Rooth added: “We’re all energised for what’s to come. We are building a growing client base and networks in new territories. Each new opportunity for the business is an opportunity for our people. The future of Torbay Pharma is bright indeed.”